RT Book,_Section
T1 COVID‐19 vaccine effectiveness in children by age groups. A population‐based study in Galicia, Spain
A1 Mallah, Narmeen
A1 Pardo Seco, Jacobo José
A1 Ares Gómez, Sonia
A1 López-Pérez, Luis-Ricardo
A1 González‐Pérez, Juan-Manuel
A1 Rosón, Benigno
A1 Otero Barrós, María Teresa
A1 Durán Parrondo, Carmen
A1 Nartallo Penas, Victoria
A1 Mirás Carballal, Susana
A1 Rodríguez-Tenreiro Sánchez, Carmen
A1 Rivero Calle, Irene
A1 Gómez Carballa, Alberto
A1 Salas Ellacuriaga, Antonio
A1 Martinón Torres, Federico
K1 Comirnaty® (Pfizer, US)
K1 COVID-19
K1 mRNA vaccine
K1 Omicron
K1 SARS-CoV-2
K1 Spain
K1 SpikeVax® (ModernaTX, Inc)
K1 Vaccine effectiveness
AB BackgroundStudies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5–11 and 12–17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.MethodsA population-based test-negative control study was undertaken in Galicia, Spain. Children 5–11-year-old received the Comirnaty® (Pfizer, US) vaccine, while those aged 12–17-year-old received the Comirnaty® (Pfizer, US) or SpikeVax® (ModernaTX, Inc) vaccine. Participants were categorized into unvaccinated (0 doses or one dose with <14 days since vaccination), partially vaccinated (only one dose with ≥14 days, or two doses with <14 days after the second dose administration), and fully vaccinated (two doses with ≥14 days after the second injection). Adjusted odds ratios (OR) and their 95% confidence intervals (CI) were estimated using multiple logistic regression models. VE was calculated as (1-OR) * 100. Stratified and sensitivity analyses were performed.ResultsIn the fully vaccinated 5–11-year-old children, VE against the Omicron variant was 44.1% (95% CI: 38.2%–49.4%). In the fully vaccinated 12–17-year-old individuals, VE was 83.4% (95% CI: 81.2%–85.3%) against Delta and 74.8% (95% CI: 58.5%–84.9%) against Omicron. Comirnaty® and SpikeVax® vaccines showed a similar magnitude of VE against Delta [Comirnaty® VE: 81.9% (95% CI: 79.3%–84.1%) and SpikeVax® VE: 85.3% (95% CI: 81.9%–88.1%)]. Comirnaty® (Pfizer, US; VE: 79.7%; 95% CI: 50.7%–92.4%) showed a slightly higher magnitude of protection against Omicron than SpikeVax® (ModernaTX, Inc), yet with an overlapping CI (VE: 74.3%; 95% CI: 56.6%–84.9%). VE was maintained in all age subgroups in both pediatric populations, but it declined over time.ConclusionsIn Galicia, mRNA VE was moderate against SARS-CoV-2 infections in the 5–11-year-old populations, but high in older children. VE declined over time, suggesting a potential need for booster dose schedules.
PB Wiley
SN 0905-6157
YR 2023
FD 2023
LK http://hdl.handle.net/10347/32941
UL http://hdl.handle.net/10347/32941
LA eng
NO Pediatric Allergy and Immunology (PAI), 34(10), 2023, e14037
NO Studies on vaccine effectiveness (VE) against COVID-19 are emerging, especially in younger children. This study showed that in settings like Spain, mRNA-based vaccines are highly effective against the Delta variant of SARS-CoV-2 in children 12–17-year-old, but the effectiveness was moderate against the Omicron variant in 5–11-year-old and 12–17-year-old populations. VE rapidly declined in both age categories, suggesting the need for booster dose schedules.
NO Agencia de Conocimiento en Salud (ACIS)—Servicio Gallego de Salud (SERGAS); Axencia Galega de Innovación; Centro de Investigacion Biomédica en Red de Enfermedades Respiratorias; European Regional Development Fund; Instituto de Salud Carlos III (ISCIII)
DS Minerva
RD 24 abr 2026